Global Chronic Obstructive Pulmonary Disease Copd Treatment Market Size 2024, Forecast To 2033
6 Mar, 2024
The chronic obstructive pulmonary disease (COPD) treatment market size has grown strongly in recent years. It will grow from $20.08 billion in 2023 to $21.09 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to the smoking epidemic and tobacco use, advancements in inhalation therapies, awareness programs and early diagnosis, government initiatives for respiratory health, research and development in pulmonology. The chronic obstructive pulmonary disease (COPD) treatment market size is expected to see strong growth in the next few years. It will grow to $26.06 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to personalized medicine and biomarker research, biologic therapies and targeted interventions, air quality concerns and environmental factors, global efforts for smoking cessation, collaborations for drug development. Major trends in the forecast period include digital health solutions for COPD management, biologic therapies for COPD, emergence of personalized medicine, combination therapies and inhalers, early diagnosis and intervention, pulmonary rehabilitation programs.
Global Chronic Obstructive Pulmonary Disease COPD Treatment Market Key Driver
The increasing prevalence of lung disease is expected to propel the growth of the chronic obstructive pulmonary disease (COPD) treatment market. Lung disease is a disorder that affects the lungs and keeps them from functioning properly. The most common lung diseases are asthma, COPD, and lung cancer. Chronic obstructive pulmonary disease (COPD) treatment is primarily used to treat lung disease, decrease the condition's progression, control the symptoms, and avoid lung damage by employing inhalers and drugs. For instance, in September 2022, according to the global initiative for Chronic obstructive lung disease (GOLD), 3.2 million people per year die from the chronic obstructive pulmonary disease (COPD), which affects an estimated 200 million people. Additionally, asthma affected 262 million people globally in 2022. Moreover, in 2023, due to lung cancer, 127,000 Americans will die in the US each year. Therefore, the increasing prevalence of lung disease is driving the growth of the chronic obstructive pulmonary disease (COPD) treatment market.
Get A Free Sample Of The Global Chronic Obstructive Pulmonary Disease COPD Treatment Market ReportGlobal Chronic Obstructive Pulmonary Disease COPD Treatment Market Segments
The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
By Geography:The regions covered in the chronic obstructive pulmonary disease (copd) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2023. Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (copd) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Chronic Obstructive Pulmonary Disease COPD Treatment Industry Players
Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc.
Get The Full Global Chronic Obstructive Pulmonary Disease COPD Treatment Market Report
Chronic Obstructive Pulmonary Disease COPD Treatment Market Overview
Chronic obstructive pulmonary disease (COPD) treatment refers to medical care given to a patient that helps manage the symptoms, slow the progression, and improve the overall quality of life of individuals with COPD. COPD is a progressive respiratory disease characterized by airflow obstruction, chronic inflammation, and damage to the lung tissue.
Chronic Obstructive Pulmonary Disease COPD Treatment Global Market Report 2023 provides data on the global chronic obstructive pulmonary disease copd treatment market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The chronic obstructive pulmonary disease copd treatment market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.